During the event, we will be showcasing our entire digital pathology portfolio. Here we are particularly proud to share our work in advancing PD-L1 testing based on the patented VirtualTripleStaining™ and its utility in automated assessment...

Affordable and scanner agnostic image analysis solutions utilizing artificial intelligence for colorimetric and morphometric analysis for oncology, neuroscience and toxicological pathology SUNNYVALE, CA--(BUSINESS WIRE)—OptraSCAN, Inc....

Join Visiopharm at USCAP 2017 and learn about how we are transforming pathology! Come see demonstrations of Analysis of PD-L1 and CD Markers within the Tumor Micro-Environment Visualize and quantify biomarker expression with heatmaps...

Munich, 20 February 2017 -- microDimensions launches a new version of its high precision whole slide alignment software Slidematch. With the new version users can align digital whole slide images from consecutive sections in brightfield and...

  In 2010, results of a phase 3 randomized controlled trial showed that targeted therapy directed against HER2 statistically significantly prolonged overall survival compared with chemotherapy alone in patients with HER2–positive...

The American Society of Clinical Oncology (ASCO), the College of American Pathologists (CAP) and the American Society for Clinical Pathology (ASCP) have issued a joint guideline on HER2 testing for patients with gastroesophageal cancers. Read...